ClinicalTrials.gg
CompletedNCT04043403Updated Oct 7, 2026Results posted

Bilateral Closed Loop Deep Brain Stimulation for Freezing of Gait Using Neural and Kinematic Feedback

An interventional study of Open Loop DBS and Adaptive (Closed Loop) DBS in Parkinson Disease, sponsored by Stanford University. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Stanford University · Not applicable, Interventional, and Treatment

How we know

Updated Oct 7, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Non-randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 19 studies in Parkinson Disease by Stanford University — 10 open to participants now, 10 under way, none of them phase 3. Parkinson Disease · Stanford University.

Enrollment
14th of 19
12 · median 20
Started
2019
with 1 other
No phase
15 of 19
9 open now
Registered
9th of 19
by date

Among the 19 studies in Parkinson Disease by Stanford University, this one is the 14th largest by enrollment, is one of 2 that started in 2019, is one of 15 with no phase, and was the 9th registered.

Parkinson Disease

4,583 studies on the registry are indexed under Parkinson Disease; 1,086 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

10 of the 19 studies in Parkinson Disease by Stanford University are open now, in 1 country. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 752 Parkinson Disease studies recruiting now, 314 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Parkinson Disease by Stanford University, or all of them as a file.
02

Study summary

Deep Brain Stimulation of the subthalamic nucleus (STN) has become a standard of care, FDA-approved treatment for Parkinson's disease, with stimulation delivered at a constant amplitude and voltage, operating in an open-loop fashion that does not respond to a patient's current state. Although gait deficits and freezing of gait may initially respond to continuous open-loop deep brain stimulation (olDBS) and medication, the symptoms often recur over time.

The episodic and predictable nature of FOG makes it well suited for adaptive DBS (aDBS) and a device that overcomes the limitations of traditional high frequency olDBS and is capable of adapting therapy either in the frequency or intensity domain transiently to treat FOG while also treating other PD signs such as tremor and bradykinesia.

The purpose of this study is to determine the feasibility of an adaptive DBS system, that responds to patient-specific neural and kinematic variables with customized DBS parameters.

03

Conditions studied

  • Parkinson Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinically-established PD
  • Meets criteria for STN DBS eligibility as part of patient's standard medical care or already implanted in the STN with Percept(TM) PC
  • The presence of complications of medication such as wearing off signs, fluctuating responses and/or dyskinesias, and/or medication tremor, and/or impairment in the quality of life on or off medication due to these factors.
  • Ability and willingness to return for study visits, at the initial programming and after three, six and twelve months of DBS.
  • Age > 18
  • Freezing of gait questionnaire (FOG-Q) score ≥ 1 and/or gait sub-score (Item 3.10) of MDS- UPDRS III ≥ 1
  • Greater than or equal to 1.2 microVp between 8-35 Hz on either the LSTN or RSTN (Percept (TM) PC cohort only)

Exclusion criteria

Exclusion Criteria:

  • Dementia
  • Untreated psychiatric disease
  • Hoehn and Yahr stage 5 on or off medication (non-ambulatory)
  • Age > 80
  • Major surgical morbidities such as severe hypertension, coagulopathy and certain metabolic conditions that might increase the risk of hemorrhage or other surgical complications
  • Presence of a cardiac pacemaker/defibrillator
  • Inability to understand/sign consent
  • Requires rTMS, ECT, MRI (Summit(R) RC+S cohort only), or diathermy
  • Are pregnant or lactating
  • Has a cranial metallic implant
  • History of seizures or epilepsy
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Device: Summit RC+S

    1. Open Loop DBS: Standard DBS therapy at a constant frequency and voltage 2. Adaptive (Closed Loop) DBS: DBS that responds to neural or kinematic features of patient's current state 3. Intermittent Open Loop DBS: Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.

    Device: Open Loop DBS · Device: Adaptive (Closed Loop) DBS · Device: Intermittent Open Loop DBS

  • Experimental
    Device: Percept PC

    1. Open Loop DBS: Standard DBS therapy at a constant frequency and voltage 2. Adaptive (Closed Loop) DBS: DBS that responds to neural features of patient's current state

    Device: Open Loop DBS · Device: Adaptive (Closed Loop) DBS

Interventions

  • DeviceOpen Loop DBS

    Standard DBS therapy at a constant frequency and voltage

  • DeviceAdaptive (Closed Loop) DBS

    DBS that responds to neural (Percept PC and Summit RC+S) or kinematic (Summit RC+S) features of patient's current state

  • DeviceIntermittent Open Loop DBS

    Control for aDBS - DBS intensity or frequency changes in a manner that mimics aDBS but is pre-determined and open loop rather than being responsive to neural or kinematic signals.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Related to Stimulation Condition

    A Customized Adverse Events and Tolerability Questionnaire will measure the absence/presence and frequency of paresthesias, and muscle twitching relative to each stimulation condition occurring during the respective study visit

    Time frame: Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)

  2. The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IV

    The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IV will: (I) Evaluate mentation, behavior, and mood (II) Evaluate a patient's activities of daily life (IV) Measure the presence/severity of dyskinesias and other complications of therapy over time Summed score ranges from 0 to 128 with higher numbers indicating worse impairment.

    Time frame: The questionnaire was assessed on the first day of a planned research visit (occurring from first research visit at month 3, through up to 3 years)

  3. MDS-UPDRS III Speech Item Score

    The MDS-UPDRS III speech item subscale will measure changes in speech related to each stimulation condition to establish safety and tolerability for speech. Subitem score is scores on ordinal scale between 0 and 4 where higher numbers indicate worse impairment.

    Time frame: Each task/condition was assessed during one day a planned research visit (occurring from second research visit at month 6, through up to 3 years)

  4. Freezing of Gait Questionnaire (FOG-Q) Score

    The Freezing of Gait Questionnaire (FOG-Q) will be used to record changes in gait over time as a measure of safety and tolerability. Scores range from 0 to 28 with higher scores indicating worse impairment.

    Time frame: The questionnaire was assessed on the first day of a planned research visit (occurring from first research visit at month 3, through up to 3 years)

Secondary outcomes

  1. Gait Parameters: Arrhythmicity

    Variability in the stride time during a gait task. Stride time is the total time required to complete one full gait cycle as measured as the time between initial ground contact of one foot and the subsequent ground contact of the same foot. The variability is then measured by taking the cofficient of variation which is the standard deviation divided by the mean. Higher variability is indicative of worse (more arrhthmic) gait.

    Time frame: Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)

  2. Gait Parameters: Mean Shank Angular Velocity

    Median of the average score per participant of the peak shank angular velocities of every stride during the gait task. Lower peak shank angular velocity is indicative of worse gait,

    Time frame: Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)

  3. Gait Parameters: Mean Gait Cycle Time

    Median of the average length of time of each stride during a gait task. Higher values are indicative of slower gait.

    Time frame: Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)

  4. Percent Time Freezing

    The percentage of the gait task was a participant frozen. Ranges from 0 to 100 where higher scores indicate worse gait.

    Time frame: Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)

  5. The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III

    Portion of the scale assesses the motor signs of PD. Each item is scored on a scale from 0 (normal) to 4 (severe), with the total possible score ranging from 0 to 132 where higher score indicate worse impairment.

    Time frame: Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)

07

Results

Posted Oct 7, 2026

Participant flow

Participants with Parkinson's disease attend 6 research visits (each lasting up to 10 days) and perform various tasks at high frequency, low frequency, and kinematic levels of intervention under different conditions (OFF deep brain stimulation, open loop deep brain stimulation, adaptive deep brain stimulation, and intermittent open loop deep brain stimulation).

Participant flow — Overall Study
MilestoneDevice: Summit RC+SDevice: Percept PC
Started93
Completed93
Not completed00

Outcome measures

PrimaryIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Related to Stimulation Condition

A Customized Adverse Events and Tolerability Questionnaire will measure the absence/presence and frequency of paresthesias, and muscle twitching relative to each stimulation condition occurring during the respective study visit

Time frame:
Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
Reported as:
Number · Events
Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability] Related to Stimulation Condition
EventsDevice: Summit RC+SDevice: Percept PC
High Frequency Stepping In Place Visit OFF Deep Brain Stimulation00
High Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation01
High Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation00
High Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation0—
High Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation00
High Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation10
High Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation10
High Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation3—
Low Frequency Stepping In Place Visit OFF Deep Brain Stimulation0—
Low Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation0—
Low Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation2—
Low Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation2—
Low Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation0—
Low Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation0—
Low Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation0—
Low Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation0—
Kinematic Stepping In Place Visit OFF Deep Brain Stimulation0—
Kinematic Stepping In Place Visit Open Loop Deep Brain Stimulation1—
Kinematic Stepping In Place Visit Adaptive Deep Brain Stimulation0—
Kinematic Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation0—
Kinematic Turning and Barrier Course OFF Deep Brain Stimulation1—
Kinematic Turning and Barrier Course Visit Open Loop Deep Brain Stimulation0—
Kinematic Turning and Barrier Course Visit Adaptive Deep Brain Stimulation0—
Kinematic Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation0—
Kinematic Stepping In Place Visit Low Frequency Open Loop Deep Brain Stimulation1—
Kinematic Stepping In Place Visit High Frequency Open Loop Deep Brain Stimulation0—
Kinematic Stepping In Place Visit Adaptive Frequency Deep Brain Stimulation0—
Kinematic Stepping In Place Visit Intermittent Frequency Open Loop Deep Brain Stimulation1—
Kinematic Turning and Barrier Course Visit Low Frequency Open Loop Deep Brain Stimulation0—
Kinematic Turning and Barrier Course Visit High Frequency Open Loop Deep Brain Stimulation0—
Kinematic Turning and Barrier Course Visit Adaptive Frequency Deep Brain Stimulation0—
Kinematic Turning and Barrier Course Visit Intermittent Frequency Open Loop Deep Brain Stimulation0—
PrimaryThe Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IV

The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IV will: (I) Evaluate mentation, behavior, and mood (II) Evaluate a patient's activities of daily life (IV) Measure the presence/severity of dyskinesias and other complications of therapy over time Summed score ranges from 0 to 128 with higher numbers indicating worse impairment.

Time frame:
The questionnaire was assessed on the first day of a planned research visit (occurring from first research visit at month 3, through up to 3 years)
Reported as:
Median · score on a scale
The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IV
score on a scaleDevice: Summit RC+SDevice: Percept PC
High Frequency Stepping In Place Visit19 (16 to 27.5)18 (17 to 20)
High Frequency Turning and Barrier Course Visit21.5 (14.75 to 33.5)13 (11.5 to 14.5)
Low Frequency Stepping In Place Visit21.5 (15.75 to 22)—
Low Frequency Turning and Barrier Course Visit14 (14 to 20)—
Kinematic Stepping In Place Visit20.5 (17 to 21.5)—
Kinematic Turning and Barrier Course19 (17 to 25.5)—
PrimaryMDS-UPDRS III Speech Item Score

The MDS-UPDRS III speech item subscale will measure changes in speech related to each stimulation condition to establish safety and tolerability for speech. Subitem score is scores on ordinal scale between 0 and 4 where higher numbers indicate worse impairment.

Time frame:
Each task/condition was assessed during one day a planned research visit (occurring from second research visit at month 6, through up to 3 years)
Reported as:
Median · score on a scale
MDS-UPDRS III Speech Item Score
score on a scaleDevice: Summit RC+SDevice: Percept PC
High Frequency Stepping In Place Visit OFF Deep Brain Stimulation1 (1 to 1.75)1.5 (1.25 to 1.75)
High Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation1 (1 to 1)1 (1 to 1.5)
High Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation1 (1 to 1)1 (1 to 1.5)
High Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation1 (1 to 1)—
High Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation1 (1 to 1)1 (1 to 1)
High Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation1 (1 to 2)1 (1 to 1.75)
High Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation1 (1 to 2)1 (0 to 2)
High Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation1 (1 to 1)—
Low Frequency Stepping In Place Visit OFF Deep Brain Stimulation1 (1 to 1)—
Low Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation1 (1 to 1)—
Low Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation1 (1 to 1)—
Low Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation1 (1 to 1)—
Low Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation1 (1 to 1.25)—
Low Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation1 (0.75 to 1.25)—
Low Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation1 (1 to 1)—
Low Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation1 (0.75 to 1.25)—
PrimaryFreezing of Gait Questionnaire (FOG-Q) Score

The Freezing of Gait Questionnaire (FOG-Q) will be used to record changes in gait over time as a measure of safety and tolerability. Scores range from 0 to 28 with higher scores indicating worse impairment.

Time frame:
The questionnaire was assessed on the first day of a planned research visit (occurring from first research visit at month 3, through up to 3 years)
Reported as:
Median · score on a scale
Freezing of Gait Questionnaire (FOG-Q) Score
score on a scaleDevice: Summit RC+SDevice: Percept PC
High Frequency Stepping In Place Visit19 (0 to 20.5)0 (0 to 3)
High Frequency Turning and Barrier Course Visit15.5 (2.75 to 20.75)0 (0 to 0)
Low Frequency Stepping In Place Visit11.5 (5 to 19.5)—
Low Frequency Turning and Barrier Course Visit9 (8 to 11)—
Kinematic Stepping In Place Visit16.5 (9 to 18.75)—
Kinematic Turning and Barrier Course Visit13 (3 to 18)—
SecondaryGait Parameters: Arrhythmicity

Variability in the stride time during a gait task. Stride time is the total time required to complete one full gait cycle as measured as the time between initial ground contact of one foot and the subsequent ground contact of the same foot. The variability is then measured by taking the cofficient of variation which is the standard deviation divided by the mean. Higher variability is indicative of worse (more arrhthmic) gait.

Time frame:
Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
Reported as:
Median · Percentage of CV (100*SD/mean)
Gait Parameters: Arrhythmicity
Percentage of CV (100*SD/mean)Device: Summit RC+SDevice: Percept PC
High Frequency Stepping In Place Visit OFF Deep Brain Stimulation19.1 (10.5 to 104.8)9.49 (8.4 to 10.6)
High Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation6.5 (5.2 to 69.9)5.1 (4.9 to 5.2)
High Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation13.6 (5.4 to 82.8)4.4 (4.3 to 6.8)
High Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation7.6 (5.0 to 89.1)—
High Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation16.0 (7.0 to 27.0)12.1 (10.9 to 13.2)
High Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation8.5 (6.9 to 16.5)7.6 (7.2 to 8.4)
High Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation7.8 (7.4 to 11.7)8.3 (7.2 to 8.7)
High Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation15.1 (6.6 to 21.6)—
Low Frequency Stepping In Place Visit OFF Deep Brain Stimulation18.8 (8.1 to 30.4)—
Low Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation7.3 (6.0 to 44.3)—
Low Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation8.3 (7.5 to 67.0)—
Low Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation12.5 (8.8 to 75.4)—
Low Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation9.9 (8.0 to 16.2)—
Low Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation8.4 (7.9 to 12)—
Low Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation9.7 (8.6 to 12.9)—
Low Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation9.2 (8.2 to 11.1)—
Kinematic Stepping In Place Visit OFF Deep Brain Stimulation127.6 (18.9 to 219.3)—
Kinematic Stepping In Place Visit Open Loop Deep Brain Stimulation8.6 (5.5 to 59.8)—
Kinematic Stepping In Place Visit Adaptive Deep Brain Stimulation14.3 (6.5 to 47.9)—
Kinematic Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation11.0 (6.8 to 62.6)—
Kinematic Turning and Barrier Course OFF Deep Brain Stimulation14.2 (7.4 to 16.5)—
Kinematic Turning and Barrier Course Visit Open Loop Deep Brain Stimulation10.6 (7.3 to 16.9)—
Kinematic Turning and Barrier Course Visit Adaptive Deep Brain Stimulation10.8 (7.7 to 20.8)—
Kinematic Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation10.1 (7.5 to 23.6)—
Kinematic Stepping In Place Visit Low Frequency Open Loop Deep Brain Stimulation7.4 (5.1 to 44.0)—
Kinematic Stepping In Place Visit High Frequency Open Loop Deep Brain Stimulation17.1 (7.0 to 37.0)—
Kinematic Stepping In Place Visit Adaptive Frequency Deep Brain Stimulation22.9 (0.8 to 35.0)—
Kinematic Stepping In Place Visit Intermittent Frequency Open Loop Deep Brain Stimulation25.2 (12.2 to 49.0)—
Kinematic Turning and Barrier Course Visit Low Frequency Open Loop Deep Brain Stimulation11.6 (6.3 to 18.5)—
Kinematic Turning and Barrier Course Visit High Frequency Open Loop Deep Brain Stimulation12.2 (6.7 to 21.5)—
Kinematic Turning and Barrier Course Visit Adaptive Frequency Deep Brain Stimulation12.0 (7.5 to 19.3)—
Kinematic Turning and Barrier Course Visit Intermittent Frequency Open Loop Deep Brain Stimulation11.2 (7.7 to 18.3)—
SecondaryGait Parameters: Mean Shank Angular Velocity

Median of the average score per participant of the peak shank angular velocities of every stride during the gait task. Lower peak shank angular velocity is indicative of worse gait,

Time frame:
Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
Reported as:
Median · degrees per second
Gait Parameters: Mean Shank Angular Velocity
degrees per secondDevice: Summit RC+SDevice: Percept PC
High Frequency Stepping In Place Visit OFF Deep Brain Stimulation29.1 (13.8 to 30.8)41.7 (33.6 to 49.8)
High Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation34.2 (30.7 to 69.2)59.1 (49.4 to 62.9)
High Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation38.4 (29.8 to 61.0)66.0 (52.3 to 68.4)
High Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation32.7 (29.6 to 87.0)—
High Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation166.7 (142.1 to 175.9)226.8 (209.3 to 244.3)
High Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation210.2 (174.4 to 256.7)262.1 (221.8 to 266.3)
High Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation202.2 (171.9 to 217.1)255.0 (224.6 to 262.0)
High Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation206.0 (184.1 to 218.5)—
Low Frequency Stepping In Place Visit OFF Deep Brain Stimulation28.5 (20.8 to 40.5)—
Low Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation38.8 (19.8 to 70.8)—
Low Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation38.4 (21.9 to 67.4)—
Low Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation39.3 (20.8 to 61.8)—
Low Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation209.8 (152.9 to 263.4)—
Low Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation225.5 (175.7 to 285.0)—
Low Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation214.9 (162.8 to 274.4)—
Low Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation224.9 (175.2 to 273.9)—
Kinematic Stepping In Place Visit OFF Deep Brain Stimulation29.2 (16.3 to 34.7)—
Kinematic Stepping In Place Visit Open Loop Deep Brain Stimulation39.2 (27.4 to 55.5)—
Kinematic Stepping In Place Visit Adaptive Deep Brain Stimulation41.3 (30.7 to 47.6)—
Kinematic Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation36.1 (29.1 to 57.9)—
Kinematic Turning and Barrier Course Visit OFF Deep Brain Stimulation174.2 (65.1 to 187.5)—
Kinematic Turning and Barrier Course Visit Open Loop Deep Brain Stimulation187.7 (183.5 to 197.7)—
Kinematic Turning and Barrier Course Visit Adaptive Deep Brain Stimulation195.5 (184.9 to 208.6)—
Kinematic Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation189.4 (175.4 to 205.7)—
Kinematic Stepping In Place Visit Low Frequency Open Loop Deep Brain Stimulation38.5 (25.8 to 66.1)—
Kinematic Stepping In Place Visit High Frequency Open Loop Deep Brain Stimulation39.6 (29.9 to 62.2)—
Kinematic Stepping In Place Visit Adaptive Frequency Deep Brain Stimulation39.6 (26.6 to 55.0)—
Kinematic Stepping In Place Visit Intermittent Frequency Open Loop Deep Brain Stimulation33.2 (28.4 to 56.2)—
Kinematic Turning and Barrier Course Visit Low Frequency Open Loop Deep Brain Stimulation195.0 (184.7 to 245.7)—
Kinematic Turning and Barrier Course Visit High Frequency Open Loop Deep Brain Stimulation213.6 (189.5 to 245.7)—
Kinematic Turning and Barrier Course Visit Adaptive Frequency Deep Brain Stimulation224.0 (190.3 to 259.9)—
Kinematic Turning and Barrier Course Visit Intermittent Frequency Open Loop Deep Brain Stimulation221.3 (193.6 to 252.5)—
SecondaryGait Parameters: Mean Gait Cycle Time

Median of the average length of time of each stride during a gait task. Higher values are indicative of slower gait.

Time frame:
Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
Reported as:
Median · Seconds
Gait Parameters: Mean Gait Cycle Time
SecondsDevice: Summit RC+SDevice: Percept PC
High Frequency Stepping In Place Visit OFF Deep Brain Stimulation1.57 (1.22 to 1.82)1.41 (1.36 to 1.45)
High Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation1.18 (1.05 to 1.31)1.27 (1.22 to 1.27)
High Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation1.24 (1.16 to 1.57)1.25 (1.23 to 1.26)
High Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation1.03 (1.00 to 1.16)—
High Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation1.01 (0.91 to 1.11)1.13 (1.13 to 1.14)
High Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation1.02 (1.00 to 1.03)1.17 (1.14 to 1.22)
High Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation1.00 (0.98 to 1.10)1.20 (1.15 to 1.25)
High Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation1.00 (0.98 to 1.13)—
Low Frequency Stepping In Place Visit OFF Deep Brain Stimulation1.57 (1.00 to 1.64)—
Low Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation1.32 (1.03 to 2.02)—
Low Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation1.39 (1.03 to 2.90)—
Low Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation1.40 (1.00 to 1.92)—
Low Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation1.13 (1.04 to 1.23)—
Low Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation1.11 (1.06 to 1.21)—
Low Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation1.14 (1.09 to 1.16)—
Low Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation1.17 (1.06 to 1.19)—
Kinematic Stepping In Place Visit OFF Deep Brain Stimulation1.44 (1.29 to 2.36)—
Kinematic Stepping In Place Visit Open Loop Deep Brain Stimulation1.18 (1.01 to 1.30)—
Kinematic Stepping In Place Visit Adaptive Deep Brain Stimulation1.12 (0.99 to 1.32)—
Kinematic Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation1.19 (1.00 to 1.42)—
Kinematic Turning and Barrier Course Visit OFF Deep Brain Stimulation1.18 (0.95 to 1.22)—
Kinematic Turning and Barrier Course Visit Open Loop Deep Brain Stimulation1.01 (0.99 to 1.12)—
Kinematic Turning and Barrier Course Visit Adaptive Deep Brain Stimulation1.02 (0.96 to 1.14)—
Kinematic Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation0.98 (0.94 to 1.09)—
Kinematic Stepping In Place Visit Low Frequency Open Loop Deep Brain Stimulation1.17 (0.98 to 1.36)—
Kinematic Stepping In Place Visit High Frequency Open Loop Deep Brain Stimulation1.11 (0.89 to 1.20)—
Kinematic Stepping In Place Visit Adaptive Frequency Deep Brain Stimulation1.02 (0.86 to 1.20)—
Kinematic Stepping In Place Visit Intermittent Frequency Open Loop Deep Brain Stimulation1.09 (0.91 to 1.27)—
Kinematic Turning and Barrier Course Visit Low Frequency Open Loop Deep Brain Stimulation1.06 (0.93 to 1.16)—
Kinematic Turning and Barrier Course Visit High Frequency Open Loop Deep Brain Stimulation0.96 (0.94 to 1.02)—
Kinematic Turning and Barrier Course Visit Adaptive Frequency Deep Brain Stimulation1.00 (0.97 to 1.07)—
Kinematic Turning and Barrier Course Visit Intermittent Frequency Open Loop Deep Brain Stimulation0.99 (0.94 to 1.06)—
SecondaryPercent Time Freezing

The percentage of the gait task was a participant frozen. Ranges from 0 to 100 where higher scores indicate worse gait.

Time frame:
Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
Reported as:
Median · Percentage of time
Percent Time Freezing
Percentage of timeDevice: Summit RC+SDevice: Percept PC
High Frequency Stepping In Place Visit OFF Deep Brain Stimulation68.8 (0.6 to 100)0 (0 to 0)
High Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation0 (0 to 31.1)0 (0 to 0)
High Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation0 (0 to 20.4)0 (0 to 0)
High Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation0 (0 to 27.8)—
High Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation41.9 (0 to 53.6)2.0 (1.4 to 2.7)
High Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation0 (0 to 7.9)0 (0 to 0)
High Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation0 (0 to 9.1)0 (0 to 0)
High Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation4.5 (0 to 11.2)—
Low Frequency Stepping In Place Visit OFF Deep Brain Stimulation1.8 (0 to 18.5)—
Low Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation0 (0 to 13.9)—
Low Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation1.34 (0 to 39.2)—
Low Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation0 (0 to 40.1)—
Low Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation0 (0 to 13.7)—
Low Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation0 (0 to 4.8)—
Low Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation0 (0 to 8.9)—
Low Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation0 (0 to 3.2)—
Kinematic Stepping In Place Visit OFF Deep Brain Stimulation67.3 (0 to 82.1)—
Kinematic Stepping In Place Visit Open Loop Deep Brain Stimulation0 (0 to 17.6)—
Kinematic Stepping In Place Visit Adaptive Deep Brain Stimulation0 (0 to 19.3)—
Kinematic Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation0 (0 to 22.7)—
Kinematic Turning and Barrier Course Visit OFF Deep Brain Stimulation13.3 (0 to 84.6)—
Kinematic Turning and Barrier Course Visit Open Loop Deep Brain Stimulation0 (0 to 16.9)—
Kinematic Turning and Barrier Course Visit Adaptive Deep Brain Stimulation0 (0 to 14.3)—
Kinematic Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation0 (0 to 19.3)—
Kinematic Stepping In Place Visit Low Frequency Open Loop Deep Brain Stimulation1.0 (0 to 9.3)—
Kinematic Stepping In Place Visit High Frequency Open Loop Deep Brain Stimulation3.7 (0 to 8.0)—
Kinematic Stepping In Place Visit Adaptive Frequency Deep Brain Stimulation6.8 (0.3 to 16.4)—
Kinematic Stepping In Place Visit Intermittent Frequency Open Loop Deep Brain Stimulation19.1 (2.3 to 19.1)—
Kinematic Turning and Barrier Course Visit Low Frequency Open Loop Deep Brain Stimulation5.2 (0 to 17.9)—
Kinematic Turning and Barrier Course Visit High Frequency Open Loop Deep Brain Stimulation2.1 (0 to 15.0)—
Kinematic Turning and Barrier Course Visit Adaptive Frequency Deep Brain Stimulation0.6 (0 to 12.5)—
Kinematic Turning and Barrier Course Visit Intermittent Frequency Open Loop Deep Brain Stimulation3.1 (0 to 15.2)—
SecondaryThe Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III

Portion of the scale assesses the motor signs of PD. Each item is scored on a scale from 0 (normal) to 4 (severe), with the total possible score ranging from 0 to 132 where higher score indicate worse impairment.

Time frame:
Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
Reported as:
Median · score on a scale
The Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III
score on a scaleDevice: Summit RC+SDevice: Percept PC
High Frequency Stepping In Place Visit OFF Deep Brain Stimulation46 (43.5 to 53.75)39 (35 to 43)
High Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation19 (11.5 to 22)36 (27.5 to 38)
High Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation16 (11.5 to 21)23 (21 to 30)
High Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation19 (11.5 to 22)—
High Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation45 (44 to 50)33.5 (27.25 to 39.75)
High Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation18 (16.75 to 21)27.5 (18 to 29.5)
High Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation17.5 (16 to 28.25)22 (13 to 34)
High Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation21.5 (18.5 to 22.5)—
Low Frequency Stepping In Place Visit OFF Deep Brain Stimulation37 (26 to 46.5)—
Low Frequency Stepping In Place Visit Open Loop Deep Brain Stimulation33 (25 to 35)—
Low Frequency Stepping In Place Visit Adaptive Deep Brain Stimulation38 (30 to 38)—
Low Frequency Stepping In Place Visit Intermittent Open Loop Deep Brain Stimulation32 (30 to 34)—
Low Frequency Turning and Barrier Course Visit OFF Deep Brain Stimulation38 (28.25 to 45.75)—
Low Frequency Turning and Barrier Course Visit Open Loop Deep Brain Stimulation21 (16.75 to 30.75)—
Low Frequency Turning and Barrier Course Visit Adaptive Deep Brain Stimulation23.5 (18 to 34.75)—
Low Frequency Turning and Barrier Course Visit Intermittent Open Loop Deep Brain Stimulation22 (17.5 to 35)—

Adverse events

Collected over Up to three years (Timeline per study plan was 6 total research visits, each separated by 3 months).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Device: Summit RC+S0/9 (0%)1/9 (11.1%)9/9 (100%)
Device: Percept PC0/3 (0%)3/3 (100%)3/3 (100%)
Most frequent serious events
Most frequent serious events
EventDevice: Summit RC+SDevice: Percept PC
FractureMusculoskeletal and connective tissue disorders0/91/3
Small Lymphocytic LymphomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/91/3
LabyrinthitisEar and labyrinth disorders0/91/3
Worsening of Parkinson's disease symptomsNervous system disorders1/90/3
Most frequent other events
Showing 10 of 13
Most frequent other events
EventDevice: Summit RC+SDevice: Percept PC
FallNervous system disorders7/93/3
TremorNervous system disorders3/91/3
Worsening of Parkinson's disease symptomsNervous system disorders3/90/3
Incision site pain/burningGeneral disorders0/91/3
Muscle TwitchingNervous system disorders2/90/3
Implant site hematomaInjury, poisoning and procedural complications1/90/3
WeaknessNervous system disorders1/90/3
Skin lesionSkin and subcutaneous tissue disorders1/90/3
DizzinessNervous system disorders1/90/3
Herpes zosterInfections and infestations1/90/3

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Device: Summit RC+SDevice: Percept PCTotal
Mean64.4 ± 4.765.2 ± 10.464.6 ± 6.0
Sex: Female, Male
Sex: Female, Male(Participants)Device: Summit RC+SDevice: Percept PCTotal
Female314
Male628
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Device: Summit RC+SDevice: Percept PCTotal
Hispanic or Latino000
Not Hispanic or Latino9312
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Device: Summit RC+SDevice: Percept PCTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American000
White9312
More than one race000
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)Device: Summit RC+SDevice: Percept PCTotal
United States9312
Disease Duration (From Parkinson's Diagnosis)
Disease Duration (From Parkinson's Diagnosis)(Years)Device: Summit RC+SDevice: Percept PCTotal
Mean12.6 ± 3.915.2 ± 1.713.3 ± 3.6
08

Study locations

1 site
  • Stanford University
    Stanford, California 94305, United States
09

References and documents

Publications

  • Negi AS, Cui C, Wilkins KB, Lambert EF, Melbourne JA, Petrucci MN, Hoffman SL, Aditham S, Diep C, Dorris HJ, Akella P, Parisi L, Gala AS, Herron JA, Bronte-Stewart HM. Low-Frequency Adaptive Deep Brain Stimulation for Parkinson's Disease. medRxiv [Preprint]. 2025 Dec 27:2025.12.17.25342333. doi: 10.64898/2025.12.17.25342333. PubMed 41480041 ↗
  • Wilkins KB, Petrucci MN, Lambert EF, Melbourne JA, Gala AS, Akella P, Parisi L, Cui C, Kehnemouyi YM, Hoffman SL, Aditham S, Diep C, Dorris HJ, Parker JE, Herron JA, Bronte-Stewart HM. Beta burst-driven adaptive deep brain stimulation for gait impairment and freezing of gait in Parkinson's disease. Brain Commun. 2025 Jul 9;7(4):fcaf266. doi: 10.1093/braincomms/fcaf266. eCollection 2025. PubMed 40677701 ↗
  • Karjagi S, Kehnemouyi YM, Petrucci MN, Parisi L, Lambert EF, Melbourne JA, Akella P, Wilkins KB, O'Day J, Dorris HJ, Diep C, Gala AS, Cui C, Hoffman SL, Acharyya P, Herron JA, Bronte-Stewart HM. Real-Time Kinematic Adaptive Deep Brain Stimulation Safely Reduces Gait Impairment and Freezing of Gait in Parkinson's Disease. medRxiv [Preprint]. 2026 Mar 2:2026.02.23.26346487. doi: 10.64898/2026.02.23.26346487. PubMed 41867218 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified participant data, including neural and kinematic data will be shared on the Data Archive for the Brain Initiative (DABI).

Supporting information: Clinical study report

Time frame: Data will be shared within one year of the final publication of the results of the current study.

Access criteria: DABI is a public repository.

Data sharing details ↗ · dabi.loni.usc.edu

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Aug 2025, 69 months.

Results were first posted in Oct 2026, 1 year 1 month after primary completion.

Of 1,297 non-industry interventional studies with no phase under Parkinson Disease, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 44. This study's 69 months is above that.

Counting every sponsor, half of 1,373 studies reached it within 25 months; a quarter within 11 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 30, 2019
First posted
Aug 2, 2019
StartActual
Oct 28, 2019
Primary completionActual
Aug 8, 2025
CompletionActual
Aug 8, 2025
Results first posted
Oct 7, 2026
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Oct 7, 2026
Primary outcomes
1 edited, 3 added, 3 removed
What changed in the outcomes
  • EditedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] relatedRelated to Stimulation ConditionTime frame: 3 Months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
  • AddedThe Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IVTime frame: The questionnaire was assessed on the first day of a planned research visit (occurring from first research visit at month 3, through up to 3 years)
  • AddedMDS-UPDRS III Speech Item ScoreTime frame: Each task/condition was assessed during one day a planned research visit (occurring from second research visit at month 6, through up to 3 years)
  • AddedFreezing of Gait Questionnaire (FOG-Q) ScoreTime frame: The questionnaire was assessed on the first day of a planned research visit (occurring from first research visit at month 3, through up to 3 years)
  • RemovedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to quality of lifeTime frame: 3 Months
  • RemovedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to speechTime frame: 6 Months
  • RemovedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to gaitTime frame: 3 Months
Oct 7, 2026
Publications
Results publication added: Negi AS, Cui C, Wilkins KB, Lambert EF, Melbourne JA, Petrucci MN, Hoffman SL, Aditham S, Diep C, Dorris HJ, Akella P, Parisi L, Gala AS, Herron JA, Bronte-Ste… PubMed 41480041 ↗; 2 more
Oct 7, 2026
Secondary outcomes
5 time frame changed, 5 description edited
What changed in the outcomes
  • Time frameGait Parameters: ArrhythmicityCollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
  • Time frameGait Parameters: Mean Shank Angular VelocityCollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
  • Time frameGait Parameters: Mean Gait Cycle TimeCollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
  • Time framePercent Time FreezingCollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
  • Time frameThe Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IIICollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
  • DescriptionGait Parameters: Arrhythmicity: how it is measured was reworded
  • DescriptionGait Parameters: Mean Gait Cycle Time: how it is measured was reworded
  • DescriptionGait Parameters: Mean Shank Angular Velocity: how it is measured was reworded
  • DescriptionPercent Time Freezing: how it is measured was reworded
  • DescriptionThe Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III: how it is measured was reworded
Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Results posted
    Publications Results publication added: Negi AS, Cui C, Wilkins KB, Lambert EF, Melbourne JA, Petrucci MN, Hoffman SL, Aditham S, Diep C, Dorris HJ, Akella P, Parisi L, Gala AS, Herron JA, Bronte-Ste… PubMed 41480041 ↗; 2 more
    Primary outcomes 1 edited, 3 added, 3 removed
    What changed in the outcomes
    • EditedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] relatedRelated to Stimulation ConditionTime frame: 3 Months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
    • AddedThe Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Parts I, II, and IVTime frame: The questionnaire was assessed on the first day of a planned research visit (occurring from first research visit at month 3, through up to 3 years)
    • AddedMDS-UPDRS III Speech Item ScoreTime frame: Each task/condition was assessed during one day a planned research visit (occurring from second research visit at month 6, through up to 3 years)
    • AddedFreezing of Gait Questionnaire (FOG-Q) ScoreTime frame: The questionnaire was assessed on the first day of a planned research visit (occurring from first research visit at month 3, through up to 3 years)
    • RemovedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to quality of lifeTime frame: 3 Months
    • RemovedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to speechTime frame: 6 Months
    • RemovedIncidence of Treatment-Emergent Adverse Events [Safety and Tolerability] related to gaitTime frame: 3 Months
    Secondary outcomes 5 time frame changed, 5 description edited
    What changed in the outcomes
    • Time frameGait Parameters: ArrhythmicityCollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
    • Time frameGait Parameters: Mean Shank Angular VelocityCollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
    • Time frameGait Parameters: Mean Gait Cycle TimeCollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
    • Time framePercent Time FreezingCollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
    • Time frameThe Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part IIICollected up to 10 days every 3 months → Each task/condition was assessed during one day at a planned research visit (occurring from first research visit at month 3, through up to 3 years)
    • DescriptionGait Parameters: Arrhythmicity: how it is measured was reworded
    • DescriptionGait Parameters: Mean Gait Cycle Time: how it is measured was reworded
    • DescriptionGait Parameters: Mean Shank Angular Velocity: how it is measured was reworded
    • DescriptionPercent Time Freezing: how it is measured was reworded
    • DescriptionThe Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III: how it is measured was reworded
    + 5 other changes: index terms, identifiers, verification date, responsible party and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04043403
Responsible party
Helen M. Bronte-Stewart (Principal Investigator, Stanford University) — Principal investigator
First posted
Aug 2, 2019
Start date
Oct 28, 2019
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025
Results posted
Oct 7, 2026
Last update
Oct 7, 2026

Study contacts

Helen M. Bronte-Stewart, MD,MSE
principal investigator · Stanford University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion